# US 2024/0390522 A1 · Gene therapy for duchenne muscular dystrophy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0390522 A1
- Document ID: US20240390522A1
- Status: Published application
- Kind: A1
- Application number: 18/696,085
- Filed: 2022-09-28
- Published: 2024-11-28
- Earliest claimed: 2021-09-28
- Assignees: University of Florida Research Foundation, Inc.
- Applicants: University of Florida Research Foundation, Incorporated
- Inventors: Hugh Lee Sweeney
- Web page: https://patentgrep.com/patent/US20240390522A1

## CPC

- A61K 48/0058: {Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct}
- A61K 48/005: {characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered}
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- C07K 14/4708: {Duchenne dystrophy}
- C12N 15/86: Viral vectors
- C07K 2319/00: Fusion polypeptide
- C07K 2319/70: containing domain for protein-protein interaction
- C12N 2750/14143: viral genome or elements thereof as genetic vector
- C12N 2800/22: Vectors comprising a coding region that has been codon optimised for expression in a respective host
- C12N 2830/008: cell type or tissue specific enhancer/promoter combination
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The disclosure provides compositions and methods for producing micro-dystrophin proteins, and the use thereof (e.g., in gene therapy). The disclosure also provides skeletal muscle-specific promoters and the use thereof (e.g., in gene therapy). The disclosure further provides catheter-based methods of delivering gene therapy vectors to skeletal muscle and/or cardiac muscle.

## Claims

### Claim 1

A recombinant nucleic acid comprising a nucleotide sequence encoding a micro-dystrophin protein comprising a utrophin N-terminus.

### Claim 2 (depends on 1)

The recombinant nucleic acid of claim 1, wherein the micro-dystrophin protein comprises the region of utrophin from the N-terminus to spectrin-like repeat 1.

### Claim 3 (depends on 1)

The recombinant nucleic acid of claim 1, wherein the micro-dystrophin protein comprises the region of utrophin from the N-terminus to spectrin-like repeat 2.

### Claim 4 (depends on 1)

The recombinant nucleic acid of claim 1, wherein the micro-dystrophin protein comprises the region of utrophin from the N-terminus to spectrin-like repeat 3.

### Claim 5 (depends on 1)

The recombinant nucleic acid of claim 1, wherein the micro-dystrophin protein comprises the region of utrophin from the N-terminus to hinge 2.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The recombinant nucleic acid of any one of claims 1-5, wherein the nucleic acid comprises a nucleotide sequence that is at least 80%, 85%, 90%, 95%, 98%, or 99% identical to any one of SEQ ID NOs: 7-12 and 22-39.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The recombinant nucleic acid of any one of claims 1-6, wherein the nucleic acid comprises the nucleotide sequence of any one of SEQ ID NOs: 7-12 and 22-39.

### Claim 8 (depends on 1, 2, 3, 4, 5)

The recombinant nucleic acid of any one of claims 1-5, wherein the nucleic acid comprises a nucleotide sequence that is at least 80%, 85%, 90%, 95%, 98%, or 99% identical to any one of SEQ ID NOs: 85-92, 126-131, 133 and 134.

### Claim 9 (depends on 1, 2, 3, 4, 5, 8)

The recombinant nucleic acid of any one of claims 1-5 and 8, wherein the nucleic acid comprises the nucleotide sequence of any one of SEQ ID NOs: 85-92, 126-131, 133 and 134.

### Claim 10 (depends on 1, 2, 3, 4, 5)

The recombinant nucleic acid of any one of claims 1-5, wherein the nucleic acid comprises a nucleotide sequence that is at least 80%, 85%, 90%, 95%, 98%, or 99% identical to any one of SEQ ID NOs: 135-148.

### Claim 11 (depends on 1, 2, 3, 4, 5, 10)

The recombinant nucleic acid of any one of claims 1-5 and 10, wherein the nucleic acid comprises the nucleotide sequence of any one of SEQ ID NOs: 135-148.

### Claim 12 (depends on 1, 2, 3, 4, 5)

The recombinant nucleic acid of any one of claims 1-5, wherein the nucleic acid comprises a nucleotide sequence that is at least 80%, 85%, 90%, 95%, 98%, or 99% identical to any one of SEQ ID NOs: 166-185.

### Claim 13 (depends on 1, 2, 3, 4, 5, 12)

The recombinant nucleic acid of any one of claims 1-5 and 12, wherein the nucleic acid comprises the nucleotide sequence of any one of SEQ ID NOs: 166-185.

### Claim 14

The recombinant nucleic acid of any preceding claim, wherein the nucleic acid comprises one or more nucleotide sequences of any one of SEQ ID NOs: 70, 72, and 207-247.

### Claim 15

The recombinant nucleic acid of any preceding claim, wherein the nucleic acid comprises at least two, at least three, at least four, or at least five nucleotide sequences of any one of SEQ ID NOs: 70, 72, and 207-247.

### Claim 16

The recombinant nucleic acid of any preceding claim comprising a promoter that is operably linked to the nucleotide sequence encoding the micro-dystrophin protein.

### Claim 17 (depends on 16)

The recombinant nucleic acid of claim 16, wherein the promoter is a cardiac-specific promoter.

### Claim 18 (depends on 17)

The recombinant nucleic acid of claim 17, wherein the cardiac-specific promoter is a cardiac troponin T (cTnT) promoter.

### Claim 19 (depends on 16)

The recombinant nucleic acid of claim 16, wherein the promoter is a skeletal muscle-specific promoter.

### Claim 20 (depends on 19)

The recombinant nucleic acid of claim 19, wherein the skeletal muscle-specific promoter is a skeletal muscle alpha-actin promoter.

### Claim 21 (depends on 19, 20)

The recombinant nucleic acid of claim 19 or 20, wherein the skeletal muscle-specific promoter comprises a nucleotide sequence that is at least 80% identical to SEQ ID NO: 78 or SEQ ID NO: 80.

### Claim 22 (depends on 19, 20, 21)

The recombinant nucleic acid of any one of claims 19-21, wherein the skeletal muscle-specific promoter comprises the nucleotide sequence of SEQ ID NO: 78 or SEQ ID NO: 80.

### Claim 23

The recombinant nucleic acid of any preceding claim, wherein the micro-dystrophin protein encoded by the nucleic acid comprises an amino acid sequence that is at least 80% identical to the amino acid sequence of any one of SEQ ID NOs: 1-6 and 13-21.

### Claim 24

The recombinant nucleic acid of any preceding claim, wherein the micro-dystrophin protein encoded by the nucleic acid comprises the amino acid sequence of any one of SEQ ID NOs: 1-6 and 13-21.

### Claim 25 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

A chimeric protein encoded by the recombinant nucleic acid of any one of claims 1-24.

### Claim 26 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

A recombinant adeno-associated virus (rAAV) vector comprising the recombinant nucleic acid of any one of claims 1-24.

### Claim 27 (depends on 26)

An rAAV particle comprising the rAAV vector of claim 26 encapsidated in an AAV capsid.

### Claim 28 (depends on 27)

The rAAV particle of claim 27, wherein the AAV capsid comprises a capsid protein derived from AAV1, AAV2, AAV3, AAV6, AAV7, AAV8, AAVrh.74, AAVrh.10, AAV2/6 or AAV9 serotypes.

### Claim 29 (depends on 26, 27, 28)

A composition comprising the rAAV particle of claim 27 or 28, or the rAAV vector of claim 26.

### Claim 30 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 27, 28, 29)

A method of treating a skeletal muscle disorder in a subject in need thereof, comprising administering to the subject the recombinant nucleic acid of any one of claims 1-24, the micro-dystrophin protein of claim 25, the rAAV particle of claim 27 or 28, or the composition of claim 29.

### Claim 31 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 27, 28, 29)

A method of treating Duchenne muscular dystrophy (DMD) in a subject in need thereof, comprising administering to the subject the recombinant nucleic acid of any one of claims 1-24, the micro-dystrophin protein of claim 25, the rAAV particle of claim 27 or 28, or the composition of claim 29.

### Claim 32 (depends on 27, 28)

A method of treating Duchenne muscular dystrophy (DMD) in a subject in need thereof, the method comprising delivering to the subject a first rAAV particle in accordance with claim 27 or 28 and a second rAAV particle in accordance with claim 27 or 28 to skeletal muscle.

### Claim 33 (depends on 32)

The method of claim 32, wherein the rAAV vector of the first rAAV particle comprises a recombinant nucleic acid comprising a cardiac-specific promoter.

### Claim 34 (depends on 32)

The method of claim 32, wherein the rAAV vector of the second rAAV particle comprises a recombinant nucleic acid comprising a skeletal-specific promoter.

### Claim 35 (depends on 32, 33, 34)

The method of any one of claims 32-34, wherein the first rAAV particle comprises a capsid protein derived from AAV9, AAVrh.74, or AAVrh.10.

### Claim 36 (depends on 32, 33, 34)

The method of any one of claims 32-34, wherein the second rAAV particle comprises a capsid protein derived from AAV8.

### Claim 37 (depends on 32, 33, 34, 35, 36)

The method of any one of claims 32-36, wherein the first and second rAAV particles are delivered by the same route of administration.

### Claim 38 (depends on 32, 33, 34, 35, 36)

The method of any one of claims 32-36, wherein the first and second rAAV particles are delivered by different routes of administration.

### Claim 39 (depends on 32, 33, 34, 35, 36, 37)

The method of any one of claims 32-37, wherein the first and second rAAV particles are delivered via one or more catheters.

### Claim 40 (depends on 32, 33, 34, 35, 36, 38)

The method of any one of claims 32-36 and 38, wherein the first and second rAAV particles are delivered via two or more catheters.

### Claim 41 (depends on 40)

The method of claim 40 comprising:
(i) introducing a catheter into the femoral artery and advancing to the heart;
(ii) delivering the first rAAV particle into the left and right coronary arteries;
(iii) retracting the catheter to the aortic arch; and
(iv) delivering the second rAAV particle to the subclavian and/or carotid arteries.

### Claim 42 (depends on 41)

The method of claim 41 further comprising (v) retracting the catheter into the descending aorta and delivering the second rAAV particle to skeletal muscle via descending aortic branches.

### Claim 43 (depends on 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42)

The method of any one of claims 32-42 further comprising administering a vasodilator to the subject prior to the delivery of the first and second rAAV particles.

### Claim 44 (depends on 43)

The method of claim 43, wherein the vasodilator is a PDE5 inhibitor.

### Claim 45 (depends on 44)

The method of claim 44, wherein the PDE5 inhibitor is sildenafil or tadalafil.

### Claim 46 (depends on 43, 44, 45)

The method of any one of claims 43-45, wherein the vasodilator is administered 10 minutes, 20 minutes, 30 minutes, 40 minutes, 50 minutes, or 1 hour prior to the delivery of first rAAV particle and/or second rAAV particle.

### Claim 47 (depends on 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46)

The method of any one of claims 32-46, wherein a blood pressure cuff is inflated on each limb at the time of delivery of the first rAAV particle and/or the second rAAV particle.

### Claim 48 (depends on 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47)

The method of any one of claims 32-47, wherein the micro-dystrophin protein encoded by the vector of the first rAAV particle comprises: an amino-terminal actin-binding domain, hinge domain 1, spectrin-like repeat 1, spectrin-like repeat 17, spectrin-like repeat 18, and spectrin-like repeat 19, and wherein the micro-dystrophin protein does not contain spectrin-like repeat 2 and/or spectrin-like repeat 3 of dystrophin.

### Claim 49 (depends on 48)

The method of claim 48, wherein the micro-dystrophin protein further comprises one or more of: spectrin-like repeat 24, hinge domain 4, and dystroglycan binding site of dystrophin.

### Claim 50 (depends on 48, 49)

The method of claim 48 or 49, wherein the micro-dystrophin protein further comprises one or more syntrophin binding domains of dystrophin.

### Claim 51 (depends on 48, 49, 50)

The method of any one of claims 48-50, wherein the micro-dystrophin protein further comprises one or more coiled coil domains of dystrophin.

### Claim 52 (depends on 48, 49, 50, 51)

The method of any one of claims 48-51, wherein the spectrin-like repeat 1 of the micro-dystrophin protein is directly coupled to the spectrin-like repeat 17.

### Claim 53 (depends on 48, 49, 50, 51, 52)

The method of any one of claims 48-52, wherein the spectrin-like repeat 19 of the micro-dystrophin protein is directly coupled to spectrin-like repeat 24.

### Claim 54 (depends on 48, 49, 50, 51, 52, 53)

The method of any one of claims 48-53, wherein the spectrin-like repeat 19 of the micro-dystrophin protein is directly coupled to hinge domain 4.

### Claim 55 (depends on 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54)

The method of any one of claims 32-54, wherein the micro-dystrophin protein encoded by the vector of the second rAAV particle comprises: an amino-terminal actin-binding domain, hinge domain 1, spectrin-like repeat 1, spectrin-like repeat 2, spectrin-like repeat 16, and spectrin-like repeat 17, and wherein the micro-dystrophin protein does not contain spectrin-like repeat 3 of dystrophin.

### Claim 56 (depends on 55)

The method of claim 55, wherein the micro-dystrophin protein further comprises one or more of: spectrin-like repeat 23, spectrin-like repeat 24, hinge domain 4, and dystroglycan binding site of dystrophin.

### Claim 57 (depends on 55, 56)

The method of claim 55 or 56, wherein the micro-dystrophin protein further comprises one or more syntrophin binding domains of dystrophin.

### Claim 58 (depends on 55, 56, 57)

The method of any one of claims 55-57, wherein the micro-dystrophin protein further comprises one or more coiled coil domains of dystrophin.

### Claim 59 (depends on 55, 56, 57, 58)

The method of any one of claims 55-58, wherein the spectrin-like repeat 2 of the micro-dystrophin protein is directly coupled to spectrin-like repeat 16.

### Claim 60 (depends on 55, 56, 57, 58, 59)

The method of any one of claims 55-59, wherein the spectrin-like repeat 17 of the micro-dystrophin protein is directly coupled to spectrin-like repeat 24.

### Claim 61 (depends on 55, 56, 57, 58, 59, 60)

The method of any one of claims 55-60, wherein the spectrin-like repeat 17 of the micro-dystrophin protein is directly coupled to hinge domain 4.

### Claim 62

The method of any one of 32-61, wherein the micro-dystrophin protein encoded by the vector of the first or second rAAV particle comprises the region of dystrophin from spectrin-like repeat 24 to the C-terminus.

### Claim 63 (depends on 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61)

The method of any one of claims 32-61, wherein the micro-dystrophin protein encoded by the vector of the first or second rAAV particle comprises the region of dystrophin from spectrin-like repeat 24 to the end of the proline rich region following the first coiled coil domain.

### Claim 64 (depends on 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61)

The method of any one of claims 32-61, wherein the micro-dystrophin protein encoded by the vector of the first or second rAAV particle comprises the region of dystrophin from hinge domain 4 to the C-terminus.

### Claim 65 (depends on 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61)

The method of any one of claims 32-61, wherein the micro-dystrophin protein encoded by the vector of the first or second rAAV particle comprises the region of dystrophin from hinge domain 4 to the end of the proline rich region following the first coiled coil domain.

### Claim 66 (depends on 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61)

The method of any one of claims 32-61, wherein the micro-dystrophin protein encoded by the vector of the first or second rAAV particle comprises the region of dystrophin from hinge domain 4 to the end of the second syntrophin binding domain.

### Claim 67 (depends on 27, 28)

A method of delivering the rAAV particle of claim 27 or 28 to a skeletal muscle in a subject, the method comprising delivering the rAAV particle via a catheter.

### Claim 68 (depends on 67)

The method of claim 67 comprising delivering the rAAV particle via a catheter to the subclavian and/or carotid arteries.

### Claim 69 (depends on 67, 68)

The method of claim 67 or 68, wherein the catheter is first introduced into the femoral artery and advanced to the subclavian and/or carotid arteries.

### Claim 70 (depends on 67, 68, 69)

The method of any one of claims 67-69, further comprising retracting the catheter into the descending aorta and delivering the rAAV particle to skeletal muscle via descending aortic branches.

### Claim 71 (depends on 67, 68, 69, 70)

The method of any one of claims 67-70, comprising administering a vasodilator.

### Claim 72

The method of 71, wherein the vasodilator is a PDE5 inhibitor.

### Claim 73 (depends on 72)

The method of claim 72, wherein the PDE5 inhibitor is sildenafil or tadalafil.

### Claim 74 (depends on 71, 72, 73)

The method of any one of claims 71-73, wherein the vasodilator is administered 10 minutes, 20 minutes, 30 minutes, 40 minutes, 50 minutes, or 1 hour prior to the delivery of the rAAV particle.

### Claim 75 (depends on 67, 68, 69, 70, 71, 72, 73, 74)

The method of any one of claims 67-74 further comprising inflating a blood pressure cuff on each limb at the time of delivery of the rAAV particle.

### Claim 76 (depends on 67, 68, 69, 70, 71, 72, 73, 74, 75)

The method of any one of claims 67-75, wherein the skeletal muscle is fast-twitch or slow-twitch.

### Claim 77

A chimeric protein comprising an amino acid sequence having at least 90%, 95%, 98%, or 99% sequence identity to of any one of SEQ ID NOs: 81-84, 93-101 and 149-155.

### Claim 78

A chimeric protein comprising the amino acid sequence of any one of SEQ ID NOs: 81-84, 93-101 and 149-155.

### Claim 79 (depends on 77, 78)

The chimeric protein of claim 77 or 78, wherein the protein comprises the amino acid sequence of any one of SEQ ID NOs: 96-101.

### Claim 80 (depends on 77, 78, 79)

The chimeric protein of any one of claims 77-79, wherein the protein comprises the amino acid sequence of SEQ ID NO: 98 or 101.

### Claim 81 (depends on 77, 78, 79, 80)

A recombinant nucleic acid encoding the chimeric protein of any one of claims 77-80.

### Claim 82 (depends on 81)

The recombinant nucleic acid of claim 81, wherein the nucleic acid comprises the nucleotide sequence of any one of SEQ ID NOs: 85-92.

### Claim 83

A recombinant nucleic acid comprising a nucleotide sequence encoding a micro-dystrophin protein comprising a utrophin N-terminus, wherein the nucleic acid comprises a sequence having at least 85%, 90%, 95%, 98%, or 99% sequence identity to of any one of SEQ ID NOs 85-92.

### Claim 84 (depends on 81, 82, 83)

An rAAV vector comprising the recombinant nucleic acid of any one of claims 81-83.

### Claim 85 (depends on 84)

An rAAV particle comprising the rAAV vector of claim 84.

### Claim 86 (depends on 25, 26, 27, 28, 77, 78, 79, 80, 84, 85)

A cell comprising the chimeric protein of any one of claims 25 and 77-80, the rAAV vector of claim 26 or 84, or the rAAV particle of any one of claims 27, 28 and 85.

### Claim 87 (depends on 86)

The cell of claim 86, wherein the cell is a mammalian cell.

### Claim 88 (depends on 86, 87)

The cell of claim 86 or 87, wherein the cell is a human cell.
